• Explore /
  • Poster
  • / Neoadjuvant durvalumab +/- tremelimumab affects the expression of immune checkpoint (IC) molecules on myeloid derived suppressor cells (MDSC) in patients (pts) with locally advanced renal cell carcinoma (RCC).

Neoadjuvant durvalumab +/- tremelimumab affects the expression of immune checkpoint (IC) molecules on myeloid derived suppressor cells (MDSC) in patients (pts) with locally advanced renal cell carcinoma (RCC).

Abstract Poster

Authors

Jaleh Fallah

Jaleh Fallah

Taussig Cancer Institute, Cleveland, OH

Jaleh Fallah , C. Marcela Diaz-Montero , Patricia A. Rayman , Wei (Auston) Wei , Laura S. Wood , Allison Martin , Kimberly D Allman , Timothy D. Gilligan , Moshe Chaim Ornstein , Jorge A. Garcia , Brian I. Rini

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Clinical Trial Registration Number

NCT02762006

Citation

J Clin Oncol 37, 2019 (suppl 7S; abstr 587)

DOI

10.1200/JCO.2019.37.7_suppl.587

Abstract #

587

Poster Bd #

F4

Abstract Disclosures

Similar Posters

First Author: Enrique Grande

First Author: Ghassan K. Abou-Alfa

First Author: Michel Bila

First Author: Matt D. Galsky